Portal de Periódicos da CAPES

Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial

2021; American Society for Microbiology; Volume: 66; Issue: 2 Linguagem: Inglês

10.1128/aac.02107-21

1098-6596

Nicolás Merchante, Sheila Cárcel, José C. Garrido-Gracia, Marta Trigo-Rodríguez, María Ángeles Esteban Moreno, Rafael León‐López, Reinaldo Espíndola-Gómez, Eduardo Aguilar Alonso, David Vinuesa García, Alberto Romero-Palacios, Inés Pérez‐Camacho, Belén Gutiérrez‐Gutiérrez, Francisco Javier Martı́nez-Marcos, Concepción Fernández-Roldán, Pedro María Martínez Pérez-Crespo, Alexandra Aceituno Caño, Eva León, Juan E. Corzo, Carmen de la Fuente, Julián Torre‐Cisneros,

SARS-CoV-2 and COVID-19 Research

The objective of this study was to investigate the efficacy and safety of early treatment with sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods included phase II, open-label, randomized, controlled clinical trial of hospitalized patients with COVID-19 pneumonia and interleukin (IL)-6 levels ≥ 40 pg/mL and/or d-dimer > 1,500 ng/mL.